Medtronic plc
Financials
Valuation Metrics
Medtronic plc's Market Cap is $119.16B. At end of 2025 it was $123.16B. Ranked #129 of 3,121 in US market (top 4%), #87 of 1,658 on NYSE (top 5%), #6 of 205 in Health Care Equipment & Services (top 3%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $119.16B | US#129/3,121 Sec#6/205 |
| Revenue | $37.54B | US#172/3,121 Sec#14/205 |
| Net Income | $5.23B | US#143/3,121 Sec#6/205 |
| Total Assets | $93.31B | US#186/3,121 Sec#7/205 |
| Net Assets | $50.23B | US#87/3,121 Sec#6/205 |
| Employees | 95,000 | US#121/3,121 Sec#8/205 |
| Value | ||
| P/E | 22.78x | US#1,302/3,121 Sec#38/205 |
| P/B | 2.37x | US#1,469/3,121 Sec#72/205 |
| PEG | 1.87x | US#1,028/3,121 Sec#48/205 |
| P/S | 3.17x | US#1,775/3,121 Sec#120/205 |
| EV/EBITDA | 15.40x | US#1,575/3,121 Sec#66/205 |
| FCF Yield | 5.15% | US#1,379/3,121 Sec#65/205 |
| Profitability | ||
| ROE | 10.41% | US#1,329/3,121 Sec#66/205 |
| ROA | 5.61% | US#950/3,121 Sec#60/205 |
| Op. Margin | 18.08% | US#1,014/3,121 Sec#32/205 |
| Revenue Growth | 9.77% | US#1,299/3,121 Sec#88/205 |
| Earnings Growth | 12.21% | US#1,032/3,121 Sec#54/205 |
| Financial Health | ||
| Debt Ratio | 84.52% | US#941/3,121 Sec#93/205 |
| Total Debt | $28.15B | US#169/3,121 Sec#8/205 |
| FCF | $6.13B | US#134/3,121 Sec#9/205 |
| Cash | $1.79B | US#448/3,121 Sec#26/205 |
| Net Debt/EBITDA | 2.79x | US#1,540/3,121 Sec#94/205 |
| Dividend | ||
| Div. Yield | 3.06% | US#597/3,121 Sec#6/205 |
| Div. Growth | 8.63% | US#587/3,121 Sec#20/205 |
| Performance | ||
| 1Y Return | -0.40% | US#1,824/3,121 Sec#127/205 |
| 1M Return | 0.78% | US#850/3,121 Sec#91/205 |
| From 52W High | -12.07% | US#893/3,121 Sec#74/205 |
| 1Y MDD | -29.48% | US#1,374/3,121 Sec#58/205 |
| Trading | ||
| Volume | 6,919,960 shares | US#229/3,121 Sec#9/205 |
| Trading Value | $642M | US#144/3,121 Sec#8/205 |
| Per Share | ||
| EPS | $4.07 | US#835/3,121 Sec#46/205 |
| BPS | $39.13 | US#635/3,121 Sec#42/205 |
Company Info
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.